[Targeted treatment of renal cell carcinoma, treatment caused side-effects and side-effect management]. / A vesesejtes daganatok célzott terápiás kezelése, a terápia okozta mellékhatások és ellátásuk.
Orv Hetil
; 158(38): 1488-1502, 2017 Sep.
Article
em Hu
| MEDLINE
| ID: mdl-28920717
Until the past decade, therapeutic options for unresectable and/or metastatic renal cell carcinoma were limited. Renal cell carcinoma is generally resistant to conventional chemotherapy, and only a small percentage of patients with renal cell carcinoma benefit from cytokine treatment. Since 2005, the advances in target-based therapy and immunotherapy modalities have created a paradigm shift in the treatment of renal cell carcinoma. Herein, we review the most up-to-date practices and emerging therapies for the treatment of renal cell carcinoma and focus on the threrapy caused side-effects and side-effect management. Orv Hetil. 2017; 158(38): 1488-1502.
Palavras-chave
biomarkerek; biomarkers; célzott (targeted) kezelések; immunotherapy; immunterápia; mTOR-gátlók; mammalian target of rapamycin inhibitors; mellékhatások; renal cell carcinoma; side-effects; targeted treatments; tirozinkináz-gátlók; tyrosine kinase inhibitors; vascular endothelial growth factor inhibitors; vascularis endothelialis növekedési faktort gátlók; vesesejtes carcinoma
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Células Renais
/
Terapia de Alvo Molecular
/
Neoplasias Renais
/
Antineoplásicos
Limite:
Humans
Idioma:
Hu
Revista:
Orv Hetil
Ano de publicação:
2017
Tipo de documento:
Article